You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD34 CD38

Showing 1 - 25 of 7,362
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Antiphospholipid Syndrome, Thrombocytopenia Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Antiphospholipid Syndrome
  • Thrombocytopenia
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023

Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • CD38-SADA:177Lu-DOTA Complex
  • (no location specified)
Aug 15, 2023

Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Evan Syndrome
  • Treatment
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023

Acquired Hemophilia Trial in Tianjin (Daratumumab)

Recruiting
  • Acquired Hemophilia
  • Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
May 5, 2023

Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)

Recruiting
  • Acute Myeloid Leukemia
  • CLL1 and CD38 dual-target CAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023

AML, ALL, Lymphoid Malignancies Trial in Birmingham (Infusion of CD34 selected hematopoietic stem cells)

Not yet recruiting
  • AML
  • +5 more
  • Infusion of CD34 selected hematopoietic stem cells
  • Birmingham, Alabama
    University of Alabama at Birmingham
Sep 14, 2023

Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)

Not yet recruiting
  • Antibody-mediated Rejection
  • Kidney Tranplant
  • Hangzhou, Zhejiang, China
    79# Qingchun Road
Jun 21, 2023

Mucopolysaccharidosis II Trial (Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII)

Not yet recruiting
  • Mucopolysaccharidosis II
  • Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII
  • (no location specified)
Dec 16, 2022

Advanced Solid Tumor Trial in New York (STI-6129)

Not yet recruiting
  • Advanced Solid Tumor
  • STI-6129
  • New York, New York
    Columbia University Medical Center
Jan 26, 2023

Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

Not yet recruiting
  • Nephrotic Syndrome
  • Genova, Italy
    IRCCS G. Gaslini
Jan 19, 2023

Light Chain (AL) Amyloidosis Trial (STI-6129)

Not yet recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • (no location specified)
Jan 11, 2023

Sickle Cell Disease Trial in Paris (DREPAGLOBE drug product)

Active, not recruiting
  • Sickle Cell Disease
  • DREPAGLOBE drug product
  • Paris, France
    Department of Biotherapy, Necker-Enfants Malades Hospital
Sep 26, 2022

B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Cyclophosphamide injection
  • +2 more
  • Charleston, South Carolina
    Hollings Cancer Center at Medical University of South Carolina
Jan 18, 2023

Acute Myeloid Leukemia Trial in Beijing, Shenzhen, Haikou (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

Recruiting
  • Acute Myeloid Leukemia
  • CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

Multiple Myeloma Trial in Irvine (89Zr-daratumumab PET/CT)

Recruiting
  • Multiple Myeloma
  • 89Zr-daratumumab PET/CT
  • Irvine, California
    Hoag Memorial Hospital Presbyterian
Aug 1, 2022

Multiple Myeloma Trial in France, Spain, United States (Daratumumab, Velcade, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Duarte, California
  • +21 more
Jan 17, 2023

MDS, Graft Vs Host Disease, Graft-versus-host-disease Trial in Miami (Busulfan, Melphalan, Fludarabine)

Not yet recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Miami, Florida
    Miami Cancer Institute
Jan 10, 2023

Retinitis Pigmentosa Trial in Sacramento (Intravitreal autologous CD34+ cells)

Recruiting
  • Retinitis Pigmentosa
  • Intravitreal autologous CD34+ cells
  • Sacramento, California
    University of California Davis
Sep 1, 2022

Hiv Trial in Philadelphia (Autologous CD4 T-Cells)

Completed
Has Results
  • Hiv
  • Autologous CD4 T-Cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Nov 13, 2022

AML Trial in Hangzhou (CD38 CAR T-cells)

Recruiting
  • AML
  • CD38 CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 13, 2022

Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Nov 28, 2023

Relapsed/Refractory Acute Myeloid Leukemia (AML) Trial in Dresden, Heidelberg (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia (AML)
  • Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
  • Gemtuzumab Ozogamicin
  • Dresden, Germany
  • +1 more
Dec 20, 2022

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)

Active, not recruiting
  • Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 10, 2023

Mitochondrial Diseases, Pearson Syndrome Trial in Ramat Gan (MNV-201)

Recruiting
  • Mitochondrial Diseases
  • Pearson Syndrome
  • MNV-201
  • Ramat Gan, Israel
    Sheba Medical Center
Aug 24, 2023